Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Tocilizumab in RA (WA18695)
NCT00721123Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2005
- Primary completion
- May 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Adverse Event (AE) Summary Over Time at 264 weeks, Summary Adverse Event Rates Over Time at 264 weeks and 1 more. Started Aug 2005; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00721123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721123.